Vertex Pharmaceuticals Inc
VRTX447.090USD
+1.990+0.45%
Handelsschluss 05/29, 16:00（ET）Kurse um 15 Minuten verzögert
114.89BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Unternehmensinformationen
Unternehmens-codeVRTX
Name des UnternehmensVertex Pharmaceuticals Inc
IPO-datumJul 24, 1991
Gegründet am1989
CEODr. Reshma Kewalramani
Anzahl der mitarbeiter6100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 24
Addresse50 Northern Avenue
StadtBOSTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02210
Telefon16173416393
Websitehttps://www.vrtx.com/
Unternehmens-codeVRTX
IPO-datumJul 24, 1991
Gegründet am1989
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
61.30K
+158.88%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
61.30K
+158.88%
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Nach RegionUSD
Name
Umsatz
Anteil
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
Aktionäre
Update-Zeit: Thu, May 15
Update-Zeit: Thu, May 15
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Aktionärsstatistik
Aktionäre
Anteil
Capital World Investors
11.11%
The Vanguard Group, Inc.
9.10%
Capital Research Global Investors
5.66%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.59%
Other
64.08%
Art
Aktionäre
Anteil
Investment Advisor
50.53%
Investment Advisor/Hedge Fund
37.23%
Research Firm
2.60%
Pension Fund
2.48%
Bank and Trust
2.04%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.30%
Insurance Company
0.17%
Individual Investor
0.15%
Other
2.07%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2908
248.19M
96.64%
-1.58M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
JP Morgan Asset Management
4.62M
1.8%
-403.93K
-8.04%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
VanEck Biotech ETF
10.56%
Tema Neuroscience and Mental Health ETF
9.99%
Invesco Nasdaq Biotechnology ETF
8.5%
ProShares Ultra Nasdaq Biotechnology
8.08%
iShares Biotechnology ETF
7.22%
Indexperts Gorilla Aggressive Growth ETF
6.87%
Federated Hermes MDT Large Cap Growth ETF
4.92%
Natixis Loomis Sayles Focused Growth ETF
4.69%
Franklin Genomic Advancements ETF
4.66%
First Trust NYSE Arca Biotechnology Index Fund
3.66%
Mehr Anzeigen
VanEck Biotech ETF
Anteil10.56%
Tema Neuroscience and Mental Health ETF
Anteil9.99%
Invesco Nasdaq Biotechnology ETF
Anteil8.5%
ProShares Ultra Nasdaq Biotechnology
Anteil8.08%
iShares Biotechnology ETF
Anteil7.22%
Indexperts Gorilla Aggressive Growth ETF
Anteil6.87%
Federated Hermes MDT Large Cap Growth ETF
Anteil4.92%
Natixis Loomis Sayles Focused Growth ETF
Anteil4.69%
Franklin Genomic Advancements ETF
Anteil4.66%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.66%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
